All In Biotech

Drug Trial Radar · NCT06697197

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Feb 17, 2025

Primary completion

Jan 4, 2029

Study completion Jan 5, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • BMS-986482Drug

    Specified dose on specified days

  • PumitamigDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)Time frame: Up to 135 days post last treatment visit
  2. Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0Time frame: Up to 135 days post last treatment visit
  3. Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0Time frame: Up to Day 28
  4. Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0Time frame: Up to 135 days post last treatment visit
  5. Number of deaths as assessed by NCI-CTCAE v5.0Time frame: Through study completion (Up to 4 years)

Locations

21 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Irvine, California · Recruiting

  • The Angeles Clinic and Research Institute - West Los Angeles Office

    Los Angeles, California · Recruiting

  • Local Institution - 0008

    Aurora, Colorado · Not yet recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Northwell Health/ RJ Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Rigshospitalet

    Copenhagen, Capital Region, Denmark · Recruiting

  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

    Marseille, Bouches-du-Rhône, France · Recruiting

  • Gustave Roussy

    Villejuif, Paris, France · Recruiting

  • General Hospital of Athens "Laiko"

    Athens, Attikí, Greece · Recruiting

  • Papageorgiou General Hospital of Thessaloniki

    Thessaloniki, Thessaloníki, Greece · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Lombardy, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Milano, Italy · Recruiting

  • Erasmus Medisch Centrum

    Rotterdam, Netherlands · Recruiting

  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)

    Amsterdam, North Holland, Netherlands · Recruiting

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [Barcelona], Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

  • Karolinska Universitetssjukhuset Solna

    Solna, Stockholms Län [se-01], Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.